Table 1.
Baseline characteristics of COVID-positive nonimmunosuppressed/immunocompromised patients and solid organ transplant recipients, diagnosed April 1, 2020 to July 31, 2022
| Variable | Overall n (%) N = 2 021 719 | Non-ISC (Male) n (%) N = 930 715 | Non-ISC (Female) n (%) N = 1 061 938 | SOT (Male) n (%) N = 17 570 | SOT (Female) n (%) N = 11 496 |
|---|---|---|---|---|---|
| Hormone replacement therapy | |||||
| Total | 44 518 (2.2%) | 7991 (0.9%) | 35 392 (3.3%) | 322 (1.8%) | 813 (7.1%) |
| Female | 36 205 (1.8%) | 35 392 (3.3%) | 813 (7.1%) | ||
| Estrogen only | 31 262 (1.8%) | <30 550a | <730a | ||
| Progesterone only | 3958 (0.2%) | 3872 (0.4%) | 86 (0.7%) | ||
| Combined | 985 (<0.1%) | <980a | <20a | ||
| Male | 8313 (0.4%) | 7991 (0.9%) | 322 (1.8%) | ||
| Age, y (Median (IQR)) | 59 (52, 69) | 60 (52, 69) | 59 (52, 69) | 62 (55, 68) | 61 (54, 68) |
| Race | |||||
| White | 1 315 057 (65%) | 615 275 (66%) | 683 599 (64%) | 10 149 (58%) | 6034 (52%) |
| Black | 235 261 (12%) | 96 938 (10%) | 132 014 (12%) | 3541 (20%) | 2768 (24%) |
| Hispanic or Latino | 194 954 (9.6%) | 87 443 (9.4%) | 103 614 (9.8%) | 2274 (13%) | 1623 (14%) |
| Other/Unknown | 276 447 (14%) | 131 059 (14%) | 142 711 (13%) | 1606 (9.1%) | 1071 (9.3%) |
| Time since transplant (mo) | |||||
| <6 | 3068 (11%) | 1895 (11%) | 1173 (10%) | ||
| 6-24 | 7239 (25%) | 4405 (25%) | 2834 (25%) | ||
| >24 | 18 759 (65%) | 11 270 (64%) | 7489 (65%) | ||
| Organ type | |||||
| Kidney | 15 648 (54%) | 9181 (52%) | 6467 (56%) | ||
| Liver | 4386 (15%) | 2602 (15%) | 1784 (16%) | ||
| Lung | 2473 (8.5%) | 1423 (8.1%) | 1050 (9.1%) | ||
| Heart | 2827 (9.7%) | 2061 (12%) | 766 (6.7%) | ||
| Other/multiple | 3732 (13%) | 2303 (13%) | 1429 (12%) | ||
| Comorbidities | |||||
| CKD | 128 783 (6.4%) | 57 517 (6.2%) | 52171 (4.9%) | 11 649 (66%) | 7446 (65%) |
| Hypertension | 632 208 (31%) | 294 367 (32%) | 315447 (30%) | 13 643 (78%) | 8751 (76%) |
| Diabetes | 309 577 (15%) | 147 721 (16%) | 146 762 (14%) | 9423 (54%) | 5671 (49%) |
| Asthma/COPD | 150 747 (7.5%) | 57 233 (6.1%) | 88 376 (8.3%) | 2783 (16%) | 2355 (20%) |
| Cancer | 149 685 (7.4%) | 68 909 (7.4%) | 74 243 (7.0%) | 4264 (24%) | 2269 (20%) |
| CAD | 150 802 (7.5%) | 90 097 (9.7%) | 51 487 (4.8%) | 6260 (36%) | 2958 (26%) |
| CHF | 108 071 (5.3%) | 53 808 (5.8%) | 45 708 (4.3%) | 5467 (31%) | 3088 (27%) |
| PVD | 113 229 (5.6%) | 53 966 (5.8%) | 51 861 (4.9%) | 4624 (26%) | 2778 (24%) |
| Liver Disease | 84 479 (4.2%) | 37 414 (4.0%) | 39 725 (3.7%) | 4518 (26%) | 2822 (25%) |
| Obesity | 601 773 (30%) | 262 039 (28%) | 323 433 (30%) | 9694 (55%) | 6607 (57%) |
| Immunosuppression | |||||
| Prednisone | 20 196 (1.0%) | 12 070 (69%) | 8126 (71%) | ||
| Tacrolimus | 21 366 (1.1%) | 12 969 (74%) | 8397 (73%) | ||
| Cyclosporine | 2668 (0.1%) | 1508 (8.6%) | 1160 (10%) | ||
| MMF | 15 989 (0.8%) | 9947 (57%) | 6042 (53%) | ||
| ATG induction | 3090 (0.2%) | 1842 (10%) | 1248 (11%) | ||
| Basiliximab induction | 2177 (0.1%) | 1411 (8.0%) | 766 (6.7%) | ||
| Variant period | |||||
| Pre-Delta | 593 590 (29%) | 278 417 (30%) | 309 095 (29%) | 3761 (21%) | 2317 (20%) |
| Prevaccination | 448 759 (22%) | 209 765 (23%) | 233 373 (22%) | 3399 (19%) | 2222 (19%) |
| Delta | 404 808 (20%) | 190 670 (20%) | 208 671 (20%) | 3342 (19%) | 2125 (18%) |
| Omicron | 574 562 (28%) | 251 863 (27%) | 310 799 (29%) | 7068 (40%) | 4832 (42%) |
| 2+ vaccination status | 675 610 (33%) | 291 299 (31%) | 372 267 (35%) | 7151 (41%) | 4893 (43%) |
ATG, antithymocyte globulin; CAD, coronary artery disease; CHF, congestive heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Delta (June 15, 2021-December 21, 2021); COVID, coronavirus disease; ISC, immunosuppressed/immunocompromised; MMF, mycophenolate mofetil; Omicron (after December 21, 2021); pre-Delta (December 10, 2020-June 14, 2021), prevaccination (before December 10, 2020); PVD, peripheral vascular disease; SOT, solid organ transplant.
a
<xx to prevent back calculation of remaining cells as per N3C small cell count policies.